Is BMS The Must Have Immuno-Oncology Accessory Of The Season?
Bristol-Myers Squibb is in the M&A hot seat, and Pfizer could be the one applying fire.
You may also be interested in...
CEO Ian Read indicated the company will wait to see if the US tax system is overhauled before completing any large-scale M&A, even as many investors are anxious to see Pfizer make an acquisition.
Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.
At ASCO, Bristol-Myers-Squibb's new Chief Scientific Officer Thomas Lynch highlighted key R&D priorities for advancing the company's cancer pipeline and staying ahead of its competitors.